FDA starts review of Summit's VEGFxPD-1 bispecific
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
The FDA has begun reviewing a bispecific drug, with one report identifying it as ivonescimab, although this name is not mentioned in all accounts. The drug in question is a VEGFxPD-1 bispecific, developed by Summit. Its potential use is as a cancer treatment.